Effector Therapeutics Inc Cash Flow Conversion Efficiency
Effector Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Effector Therapeutics Inc (EFTR) has a cash flow conversion efficiency ratio of -8.800x as of March 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.28 Million) by net assets ($827.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Effector Therapeutics Inc (2019–2023)
Cash flow conversion efficiency of Effector Therapeutics Inc from 2019 to 2023. This chart illustrates how Effector Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Effector Therapeutics Inc for real-time trading data and today's change.
Effector Therapeutics Inc Cash Flow Conversion Ratio Explained
Effector Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Effector Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Effector Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Effector Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Invesque Inc
TO:IVQ
|
0.011x |
|
Carzo Holdings Bhd
KLSE:03048
|
-0.011x |
|
YUMY CANDY COMPANY INC.
F:FWR0
|
-0.003x |
|
Internet Thailand Public Company Limited
F:IE2A
|
0.148x |
|
Coronado Global Resources Inc
AU:CRN
|
-0.215x |
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
-0.154x |
|
LD + HOUSES PCL FGN BA 1
F:LHOG
|
0.073x |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
0.089x |
Annual Cash Flow Conversion Efficiency for Effector Therapeutics Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Effector Therapeutics Inc from 2019 to 2023. Review Effector Therapeutics Inc (EFTR) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-5.79 Million | $-29.55 Million | 5.099x | +176.71% |
| 2022-12-31 | $3.90 Million | $-25.90 Million | -6.648x | -361.66% |
| 2021-12-31 | $17.28 Million | $-24.89 Million | -1.440x | -1276.40% |
| 2020-12-31 | $-132.25 Million | $13.84 Million | -0.105x | -105.25% |
| 2019-12-31 | $-13.84 Million | $-27.60 Million | 1.994x | -- |
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more